The anticoagulation length of therapy and risk of new adverse events in venous thromboembolism (ALTERNATIVE) study: Design and survey results
The Anticoagulation Length of Therapy and Risk of New Adverse Events In Venous Thromboembolism (ALTERNATIVE) study was designed to compare the benefits and harms of different treatment options for extended treatment of venous thromboembolism (VTE). In this paper, we describe the study cohort, survey...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731472/?tool=EBI |
| _version_ | 1811295009810415616 |
|---|---|
| author | Cecilia Portugal Margaret C. Fang Alan S. Go Hui Zhou John Chang Priya Prasad Dongjie Fan Elisha A. Garcia Sue Hee Sung Kristi Reynolds |
| author_facet | Cecilia Portugal Margaret C. Fang Alan S. Go Hui Zhou John Chang Priya Prasad Dongjie Fan Elisha A. Garcia Sue Hee Sung Kristi Reynolds |
| author_sort | Cecilia Portugal |
| collection | DOAJ |
| description | The Anticoagulation Length of Therapy and Risk of New Adverse Events In Venous Thromboembolism (ALTERNATIVE) study was designed to compare the benefits and harms of different treatment options for extended treatment of venous thromboembolism (VTE). In this paper, we describe the study cohort, survey data collection, and preliminary results. We identified 39,605 adult patients (age ≥ 18 years) from two large integrated health care delivery systems who were diagnosed with incident VTE and received initial anticoagulation therapy of 3 months or longer. A subset of the cohort (12,737) was invited to participate in a survey. Surveys were completed in English, Spanish or Mandarin via a mailed questionnaire, an online secure web link, or telephone. The survey domains included demographics, personal medical history, anticoagulant treatment history, anticoagulant treatment satisfaction, health-related quality of life and health literacy. A total of 5,017 patients participated in the survey for an overall response rate of 39.4%. The mean (SD) age of the survey respondents was 63.0 (14.5) years and self-reported race was 76.0% White/European, 11.1% Black/African American, and 3.8% Asian/Pacific Islander and 14.0% reported Hispanic ethnicity. Sixty percent of respondents completed the web survey, while 29.0% completed the mail-in paper survey, and 11.0% completed the survey via telephone. The ALTERNATIVE Study will address knowledge gaps by comparing several treatment alternatives for the extended management of VTE so that this information could be used by patients and clinicians to make more informed, patient-centered treatment choices. |
| first_indexed | 2024-04-13T05:26:09Z |
| format | Article |
| id | doaj.art-d1ca447382844711a8769cf880b01736 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-13T05:26:09Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-d1ca447382844711a8769cf880b017362022-12-22T03:00:35ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-011712The anticoagulation length of therapy and risk of new adverse events in venous thromboembolism (ALTERNATIVE) study: Design and survey resultsCecilia PortugalMargaret C. FangAlan S. GoHui ZhouJohn ChangPriya PrasadDongjie FanElisha A. GarciaSue Hee SungKristi ReynoldsThe Anticoagulation Length of Therapy and Risk of New Adverse Events In Venous Thromboembolism (ALTERNATIVE) study was designed to compare the benefits and harms of different treatment options for extended treatment of venous thromboembolism (VTE). In this paper, we describe the study cohort, survey data collection, and preliminary results. We identified 39,605 adult patients (age ≥ 18 years) from two large integrated health care delivery systems who were diagnosed with incident VTE and received initial anticoagulation therapy of 3 months or longer. A subset of the cohort (12,737) was invited to participate in a survey. Surveys were completed in English, Spanish or Mandarin via a mailed questionnaire, an online secure web link, or telephone. The survey domains included demographics, personal medical history, anticoagulant treatment history, anticoagulant treatment satisfaction, health-related quality of life and health literacy. A total of 5,017 patients participated in the survey for an overall response rate of 39.4%. The mean (SD) age of the survey respondents was 63.0 (14.5) years and self-reported race was 76.0% White/European, 11.1% Black/African American, and 3.8% Asian/Pacific Islander and 14.0% reported Hispanic ethnicity. Sixty percent of respondents completed the web survey, while 29.0% completed the mail-in paper survey, and 11.0% completed the survey via telephone. The ALTERNATIVE Study will address knowledge gaps by comparing several treatment alternatives for the extended management of VTE so that this information could be used by patients and clinicians to make more informed, patient-centered treatment choices.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731472/?tool=EBI |
| spellingShingle | Cecilia Portugal Margaret C. Fang Alan S. Go Hui Zhou John Chang Priya Prasad Dongjie Fan Elisha A. Garcia Sue Hee Sung Kristi Reynolds The anticoagulation length of therapy and risk of new adverse events in venous thromboembolism (ALTERNATIVE) study: Design and survey results PLoS ONE |
| title | The anticoagulation length of therapy and risk of new adverse events in venous thromboembolism (ALTERNATIVE) study: Design and survey results |
| title_full | The anticoagulation length of therapy and risk of new adverse events in venous thromboembolism (ALTERNATIVE) study: Design and survey results |
| title_fullStr | The anticoagulation length of therapy and risk of new adverse events in venous thromboembolism (ALTERNATIVE) study: Design and survey results |
| title_full_unstemmed | The anticoagulation length of therapy and risk of new adverse events in venous thromboembolism (ALTERNATIVE) study: Design and survey results |
| title_short | The anticoagulation length of therapy and risk of new adverse events in venous thromboembolism (ALTERNATIVE) study: Design and survey results |
| title_sort | anticoagulation length of therapy and risk of new adverse events in venous thromboembolism alternative study design and survey results |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731472/?tool=EBI |
| work_keys_str_mv | AT ceciliaportugal theanticoagulationlengthoftherapyandriskofnewadverseeventsinvenousthromboembolismalternativestudydesignandsurveyresults AT margaretcfang theanticoagulationlengthoftherapyandriskofnewadverseeventsinvenousthromboembolismalternativestudydesignandsurveyresults AT alansgo theanticoagulationlengthoftherapyandriskofnewadverseeventsinvenousthromboembolismalternativestudydesignandsurveyresults AT huizhou theanticoagulationlengthoftherapyandriskofnewadverseeventsinvenousthromboembolismalternativestudydesignandsurveyresults AT johnchang theanticoagulationlengthoftherapyandriskofnewadverseeventsinvenousthromboembolismalternativestudydesignandsurveyresults AT priyaprasad theanticoagulationlengthoftherapyandriskofnewadverseeventsinvenousthromboembolismalternativestudydesignandsurveyresults AT dongjiefan theanticoagulationlengthoftherapyandriskofnewadverseeventsinvenousthromboembolismalternativestudydesignandsurveyresults AT elishaagarcia theanticoagulationlengthoftherapyandriskofnewadverseeventsinvenousthromboembolismalternativestudydesignandsurveyresults AT sueheesung theanticoagulationlengthoftherapyandriskofnewadverseeventsinvenousthromboembolismalternativestudydesignandsurveyresults AT kristireynolds theanticoagulationlengthoftherapyandriskofnewadverseeventsinvenousthromboembolismalternativestudydesignandsurveyresults AT ceciliaportugal anticoagulationlengthoftherapyandriskofnewadverseeventsinvenousthromboembolismalternativestudydesignandsurveyresults AT margaretcfang anticoagulationlengthoftherapyandriskofnewadverseeventsinvenousthromboembolismalternativestudydesignandsurveyresults AT alansgo anticoagulationlengthoftherapyandriskofnewadverseeventsinvenousthromboembolismalternativestudydesignandsurveyresults AT huizhou anticoagulationlengthoftherapyandriskofnewadverseeventsinvenousthromboembolismalternativestudydesignandsurveyresults AT johnchang anticoagulationlengthoftherapyandriskofnewadverseeventsinvenousthromboembolismalternativestudydesignandsurveyresults AT priyaprasad anticoagulationlengthoftherapyandriskofnewadverseeventsinvenousthromboembolismalternativestudydesignandsurveyresults AT dongjiefan anticoagulationlengthoftherapyandriskofnewadverseeventsinvenousthromboembolismalternativestudydesignandsurveyresults AT elishaagarcia anticoagulationlengthoftherapyandriskofnewadverseeventsinvenousthromboembolismalternativestudydesignandsurveyresults AT sueheesung anticoagulationlengthoftherapyandriskofnewadverseeventsinvenousthromboembolismalternativestudydesignandsurveyresults AT kristireynolds anticoagulationlengthoftherapyandriskofnewadverseeventsinvenousthromboembolismalternativestudydesignandsurveyresults |